Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas

Part of paid clinical trials in Houston, Texas.

Sponsor
Bantam Pharmaceuticals
Study ID
NCT06792734
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Lymphoma, B-Cell

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BTM-3566 — DRUG
    Oral Solution

Study Details

The goal of this clinical trial is to learn if BMT-3566 can safety be given to adult patients with relapsed or refractory mature b cell lymphomas. It will also learn how well BTM-3566 works to treat relapsed or refractory mature b cell lymphomas. The main questions it aims to answer are: What are the side effects of BTM-3566 at different doses? What are the levels of BTM-3566 in the blood at different timepoints around dosing? What is the clinical benefit of BTM-3566 in treating cancer (i.e. how well does it slow or stop disease progression)? Participants will: Take BTM-3566 in 14-day periods with 7 days of dosing followed by 7 days of no dosing Visit the clinic regularly for checkups and tests Keep a diary of their dosing and weight

Key Dates

Start date
Feb 14, 2025
Status verified
Sep 2025
Primary completion
Feb 28, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BTM-3566 Treatment
    BTM-3566 Oral Solution

Primary Outcome Measure

Adverse Event and dose-limiting toxicity event rates [ Time Frame: 24 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Luhua M Wang, MD
713-792-2121
Luhua M Wang, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX

Related Studies